Telix Pharmaceuticals Limited
TLX
$17.60
$0.301.73%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.75% | 12.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.75% | 12.79% | |||
| Cost of Revenue | -2.75% | 4.09% | |||
| Gross Profit | -2.75% | 18.99% | |||
| SG&A Expenses | -2.75% | 15.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -2.74% | 109.89% | |||
| Total Operating Expenses | -2.75% | 14.09% | |||
| Operating Income | -2.75% | 0.45% | |||
| Income Before Tax | -2.75% | 18.85% | |||
| Income Tax Expenses | -2.75% | 122.22% | |||
| Earnings from Continuing Operations | -2.75% | -11.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.75% | -11.79% | |||
| EBIT | -2.75% | 0.45% | |||
| EBITDA | -2.75% | -6.56% | |||
| EPS Basic | -2.96% | -12.50% | |||
| Normalized Basic EPS | -2.70% | 32.14% | |||
| EPS Diluted | -2.59% | -13.06% | |||
| Normalized Diluted EPS | -2.84% | 31.06% | |||
| Average Basic Shares Outstanding | 0.00% | 0.94% | |||
| Average Diluted Shares Outstanding | 0.00% | 1.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
